Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expands By 149.0%

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) was the recipient of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 576,400 shares, an increase of 149.0% from the January 31st total of 231,500 shares. Based on an average daily trading volume, of 281,000 shares, the short-interest ratio is currently 2.1 days.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. BML Capital Management LLC boosted its position in Oramed Pharmaceuticals by 62.1% during the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after acquiring an additional 837,153 shares in the last quarter. Peapod Lane Capital LLC bought a new stake in shares of Oramed Pharmaceuticals in the 4th quarter worth approximately $550,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Oramed Pharmaceuticals in the 3rd quarter worth approximately $272,000. XTX Topco Ltd boosted its position in shares of Oramed Pharmaceuticals by 59.7% in the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 9,242 shares in the last quarter. Finally, Marquette Asset Management LLC bought a new stake in shares of Oramed Pharmaceuticals in the 4th quarter worth approximately $81,000. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 19th.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ:ORMP opened at $2.09 on Friday. Oramed Pharmaceuticals has a 1 year low of $2.00 and a 1 year high of $3.48. The company has a market cap of $84.25 million, a PE ratio of 19.00 and a beta of 1.66. The stock’s 50-day moving average is $2.31 and its 200 day moving average is $2.36.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.